A durable response was found in patients with synovial sarcoma treated with ADP-A2M4 (Adaptimmune Therapeutics), according to data presented at the virtual Connective Tissue Oncology Society (CTOS) annual meeting.
Updated data from the phase 1 trial, which included 16 patients with synovial sarcoma treated with ADP-A2M4, found that 44% had confirmed partial responses and 94% had disease control. The median duration of response was 28 weeks, with 2 patients having partial response ongoing beyond 72 weeks at the time of the data cut-off.
At the data cut-off, 11 of the 16 patients were alive and median overall survival had not been reached.
“The impact on patients treated with ADP-A2M4 is transformative, as they benefit from a durable response from a single treatment. This leads to the highest quality of life I have been able to provide patients with synovial sarcoma after treatment,” said Dr. Brian Van Tine, Associate Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine in a press release.“Data from this trial have enabled rapid execution of our pivotal trial, SPEARHEAD-1, and support our aim to commercialize ADP-A2M4 as the first engineered TCR T-cell product in the US in 2022,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer, in the release. “However, this is only the beginning of the tremendous potential of our products targeting MAGEA4. We will rapidly pursue additional indications, starting with the Phase 2 trial in gastroesophageal cancers with ADP-A2M4CD8 expected to initiate in the first half of 2021.”
Read the full press release here.